ABBV · Healthcare

AbbVie Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

Quarterly Dividend DeclarationImportance 9 · Surprise 6
AbbVie declared a quarterly dividend of $1.73 per share. The dividend was reported alongside second-quarter 2026 revenue of $16.99 billion and adjusted EPS of $3.65. AbbVie continues to be characterized as having a…

Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion, with the transaction priced at $135.11 per Apogee share. The acquisition is intended to expand AbbVie’s anti-inflammatory portfolio, including…
Outstanding IndebtednessImportance 64 · Surprise 42
AbbVie launched a $10 billion bond sale to finance its pending Apogee Therapeutics acquisition. Earlier reporting indicated the company was seeking to raise at least $8 billion in debt for the transaction. The debt…
Guidance / OutlookImportance 51 · Surprise 60
AbbVie reduced its 2026 EPS outlook to reflect the pending Apogee acquisition. The transaction is expected to dilute adjusted EPS by $0.14, partially offsetting the benefit of the 2026 revenue guidance increase. The…

Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion, with the transaction priced at $135.11 per Apogee share. The acquisition is intended to expand AbbVie’s anti-inflammatory portfolio, including…
Outstanding IndebtednessImportance 64 · Surprise 42
AbbVie launched a $10 billion bond sale to finance its pending Apogee Therapeutics acquisition. Earlier reporting indicated the company was seeking to raise at least $8 billion in debt for the transaction. The debt…
Revenue Performance and MixImportance 54 · Surprise 40
AbbVie reported second-quarter 2026 revenue of $16.99 billion, up 10.2% year over year and above analyst expectations. Skyrizi and Rinvoq delivered strong growth and helped offset declining Humira revenue. Adjusted EPS…
Guidance / OutlookImportance 51 · Surprise 60
AbbVie reduced its 2026 EPS outlook to reflect the pending Apogee acquisition. The transaction is expected to dilute adjusted EPS by $0.14, partially offsetting the benefit of the 2026 revenue guidance increase. The…

Outstanding IndebtednessImportance 64 · Surprise 42
AbbVie launched a $10 billion bond sale to finance its pending Apogee Therapeutics acquisition. Earlier reporting indicated the company was seeking to raise at least $8 billion in debt for the transaction. The debt…
Regulatory Approval MilestonesImportance 38 · Surprise 60
The U.S. Food and Drug Administration accepted Allergan Aesthetics’ supplemental Biologics License Application for BOTOX Cosmetic for review on August 4, 2026. The application seeks approval for the temporary…